 A systematic review and meta-analysis assessed the efficacy and safety of therapeutic human papillomavirus, HPV, vaccines for treating cervical intrapithelial neoplasia of grade 2, or 3, CIN two-thirds. The study included 12 trials with a total of 734 women and found that the therapeutic vaccine achieved regression of CIN two-thirds lesions at an overall proportion of 0.54 compared to 0.27 in the placebo group. The pooled proportion of high-risk human papillomavirus, our HPV, clearance was also higher in the vaccinated group, 0.42, compared to the control group, 0.17. No significant unsolicited adverse events were consistently reported. However, implementation issues such as feasibility, acceptability, adoption, and cost-effectiveness need further study. This article was authored by Pata Bossu, Li Zhong, Catherine Sovajet, and others. We are article.tv, links in the description below.